Sold as Brukinsa. Every FDA application for this active ingredient.
As of Nov 15, 2026, FDA lists 2 applications for Zanubrutinib (sold as Brukinsa), first approved Nov 14, 2019, with 5 new uses approved and 0 published complete response letters.
| Product | Part | Spending, 2025 | Change | Beneficiaries |
|---|---|---|---|---|
| Brukinsa | Part D | $2.56B | +48% | 23,841 |
| MACE and BTK InhibitorsHematologic Cancer, MACE · University Hospital, Caen | Phase 4 | Not yet recruiting | Nov 6, 2026 |
| Prophylactic Strategies for Mitigating Central Nervous System Relapse in Diffuse Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma (DLBCL) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Phase 2 | Not yet recruiting | Nov 4, 2026 |
| A Trial to Evaluate the Efficacy and Safety of a Fitness-adapted Thera-py Approach With Either Continuous Zanubrutinib Monotherapy or Time-limited Zanubrutinib + Sonrotoclax in Older and/or Frail Patients With Treatment-naïve CLLCLL (Chronic Lymphocytic Leukemia) · German CLL Study Group | Phase 2 | Not yet recruiting | Oct 27, 2026 |
| Epcoritamab as Consolidative Therapy for Waldenstr(SqrRoot)(Delta)m Macroglobulinemia (WM) Treated With a Bruton Tyrosine Kinase Inhibitor (BTKi)Waldenstrom Macroglobulinemia · National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 | Not yet recruiting | Oct 20, 2026 |
| Zanubrutinib Plus Lenalidomide for Frail Elderly Patients With Newly Diagnosed PCNSLPrimary Central Nervous System Lymphoma (PCNSL), Zanubrutinib · Xiaohui Ren | Phase 2 | Recruiting | Sep 24, 2026 |
| Zanubrutinib and Sonrotoclax for the Treatment of Relapsed Chronic Lymphocytic Leukemia /Small Lymphocytic Leukemia, ZeuS-2 TrialRecurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma · City of Hope Medical Center | Phase 2 | Not yet recruiting | Sep 10, 2026 |
| A Study of Zanubrutinib, Obinutuzumab, and Sonrotoclax in People With Mantle Cell LymphomaMantle Cell Lymphoma · Memorial Sloan Kettering Cancer Center | Phase 2 | Not yet recruiting | Sep 2, 2026 |
| Study of Zanubrutinib in Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL)Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma · The Lymphoma Academic Research Organisation | Phase 2 | Not yet recruiting | Jul 31, 2026 |
| Nov 14, 2019 | BrukinsaNDA 213217 · New molecular entity | Beone Medicines USA | 8 | Discontinued |
| Jun 10, 2025 | BrukinsaNDA 218785 · New dosage form | Beone Medicines USA | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA